Psoriasis Therapy Maintains Skin Clearance Through 5 Years
Results from the SCULPTURE study showed that secukinumab (Cosentyx) improved psoriasis symptoms and quality of life through 5 years of treatment among patients with moderate to severe psoriasis. Robert Bissonnette, MD, and colleagues presented these findings at the American Academy of Dermatology annual meeting in San Diego, CA.
In the SCULPTURE study, 168 participants who achieved a Psoriasis Area and Severity Index (PASI) 75 after 12 weeks of treatment continued to receive 300 mg of subcutaneous secukinumab every 4 weeks for 1 year followed by a 3-year extension of the treatment regimen. A total of 126 patients who completed the extension phase continued to receive secukinumab through year 5. The researchers assessed PASI, absolute PASI, body surface area (BSA), dermatology quality of life (DQLI), and safety and tolerability from year 1 to year 5.
Potential Psoriasis Therapy Associated With Improved Outcomes
Psoriasis Therapy Significantly Reduces Aortic Inflammation
After 1 year of treatment, 88.9% of participants achieved PASI 75, 68.5% of participants achieved PASI 90, and 43.8% of participants achieved PASI 100. Responses rates to secukinumab were sustained through 5 years of treatment, with 88.5% of participants achieving PASI 75, 66.4% of participants achieving PASI 90, and 41% of participants achieving PASI 100. Additionally, the researchers found that PASI responses were consistent across different analyses.
Overall, secukinumab was associated with a 90% improvement in psoriasis through year 5. The mean improvement in absolute PASI from baseline to year 1 and to year 5 were 91.1% and 90.1%, respectively. In addition, the absolute PASI responses of 1 or greater, 2 or greater, or 3 or greater were sustain from year 1 to year 5, as well as BSA responses of 1 or greater, 2 or greater, or 3 or greater.
Responses of 0/1 on the DLQI were reported by 72.7% of participants at year 1 and 65.5% of participants at year 5, with two-thirds of participants reporting that skin disease did not impact their life through 5 years of treatment.
In addition, no new safety signals were identified and the safety profile of secukinumab remained favorable through 5 years of treatment.
“Secukinumab treatment sustained high levels of skin clearance and improvement in quality of life with a favorable safety profile through 5 years,” the researchers concluded. “Patients experienced long-lasting relief from the burden of psoriasis.”
Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. Presented at: 2018 American Academy of Dermatology (AAD) Annual Meeting; February 16-20, 2018; San Diego, California. Abstract 6813.